Therapeutic Opportunities from Tumour Biology in Metastatic Colon Cancer
Overview
Authors
Affiliations
Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer. While improvements in quality of life and patient survival have been made over the past 10 years, the majority of patients with metastatic colorectal cancer will die from their disease. As knowledge of the biology of colon cancer and its invasion/metastasis programme evolve, this presents new therapeutic opportunities for pharmacological and genetic intervention. This review discusses the current approaches to metastatic colorectal cancer therapy, details genomic and biological variance between primary and metastatic tumours, and highlights approaches for harnessing these differences to improve therapy.
The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis.
Sahu S, Dey S, Nabinger S, Jiang G, Bates A, Tanaka H Sci Rep. 2019; 9(1):15803.
PMID: 31676795 PMC: 6825151. DOI: 10.1038/s41598-019-52225-2.
Serine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer.
Zhao Z, Li H, Wang C, Xu W, Sun J, Zhao W Med Oncol. 2015; 32(4):112.
PMID: 25761858 DOI: 10.1007/s12032-015-0524-z.
Cytohesins/ARNO: the function in colorectal cancer cells.
Pan T, Sun J, Hu J, Hu Y, Zhou J, Chen Z PLoS One. 2014; 9(3):e90997.
PMID: 24618737 PMC: 3950297. DOI: 10.1371/journal.pone.0090997.
Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies.
Frick V, Rubie C, Ghadjar P, Faust S, Wagner M, Graber S Tumour Biol. 2010; 32(1):189-96.
PMID: 20865359 DOI: 10.1007/s13277-010-0112-y.
Src activity alters alpha3 integrin expression in colon tumor cells.
Kline C, Olson T, Irby R Clin Exp Metastasis. 2008; 26(2):77-87.
PMID: 18839319 DOI: 10.1007/s10585-008-9215-x.